Vaxcyte (PCVX) Total Current Liabilities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Total Current Liabilities data on file, last reported at $242.1 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 149.58% year-over-year to $242.1 million in Q1 2026; TTM through Mar 2026 was $242.1 million, a 149.58% increase from a year earlier, with the FY2025 full-year figure at $205.8 million, up 46.78% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $242.1 million, up from $205.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for PCVX reached as high as $242.1 million in Q1 2026 and fell as low as $27.2 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $106.7 million across 5 years, with a median of $87.1 million in 2024.
• Across the five-year window, Total Current Liabilities tumbled 50.47% in 2022 and jumped 258.64% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $40.5 million in 2022, then soared by 258.64% to $145.3 million in 2023, then retreated by 3.55% to $140.2 million in 2024, then soared by 46.78% to $205.8 million in 2025, then increased by 17.66% to $242.1 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $242.1 million in Q1 2026, $205.8 million in Q4 2025, and $200.0 million in Q3 2025.